₹8,447 crore in medicine overcharging claims remain outstanding | Data Point
The National Pharmaceutical Pricing Authority (NPPA) reports that 8,447 crore in medicine overcharging claims remain unrecovered as of March 2026. The data highlights significant gaps in recovery efforts and the impact of medicine costs on household healthcare expenditure.
Why it matters
This data point underscores the challenges in regulating pharmaceutical pricing and the financial burden of healthcare on the public.
₹8,447 crore in medicine overcharging claims remain outstanding | Data Point left https://th-i.thgim.com/public/videos/shorts/uz94v5/article71626694.ece/alternates/FREE_1200/Thumbnail_Devyanshi%203.png The National Pharmaceutical Pricing Authority (NPPA) had demanded ₹10,029.8 crore from pharmaceutical companies for overcharging on medicines, including interest, as of March 31, 2026. Of this, only ₹1,582.4 crore had been recovered, leaving ₹8,447.4 crore outstanding. In this video, we examine the NPPA’s recovery record, the financial years that saw the highest number of overcharging cases, and the status of outstanding claims.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in